These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 11478033

  • 1. [Left ventricular hypertrophy: pathogenesis, diagnosis and therapy].
    Nagy V.
    Orv Hetil; 2001 Jul 01; 142(26):1375-83. PubMed ID: 11478033
    [Abstract] [Full Text] [Related]

  • 2. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C.
    Ital Heart J; 2004 Jul 01; 5(7):505-10. PubMed ID: 15487267
    [Abstract] [Full Text] [Related]

  • 3. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG, Schannwell CM, Schwartzkopff B, Strauer BE.
    Herz; 2003 Dec 01; 28(8):764-78. PubMed ID: 14689112
    [Abstract] [Full Text] [Related]

  • 4. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
    Agabiti-Rosei E.
    Blood Press Suppl; 1997 Dec 01; 2():13-5. PubMed ID: 9495620
    [Abstract] [Full Text] [Related]

  • 5. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy.
    Agabiti-Rosei E, Muiesan ML, Salvetti M.
    J Am Soc Nephrol; 2006 Apr 28; 17(4 Suppl 2):S104-8. PubMed ID: 16565230
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V, Devereux RB.
    Minerva Cardioangiol; 2002 Jun 28; 50(3):169-74. PubMed ID: 12107398
    [Abstract] [Full Text] [Related]

  • 9. [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].
    Schiemann AL, Stimpel M.
    Praxis (Bern 1994); 1997 Jul 02; 86(27-28):1101-6. PubMed ID: 9324718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May 02; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 12. Antihypertensive treatment is associated with improved left ventricular geometry: the Rotterdam Study.
    Bleumink GS, Deinum J, Mosterd A, Witteman JC, Hofman A, Stricker BH.
    Pharmacoepidemiol Drug Saf; 2004 Oct 02; 13(10):703-9. PubMed ID: 15386731
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
    Galderisi M, Cicala S, De Simone L, Caso P, Petrocelli A, Pietropaolo L, Celentano A, Mininni N, de Divitiis O.
    Ital Heart J; 2001 Sep 02; 2(9):677-84. PubMed ID: 11666096
    [Abstract] [Full Text] [Related]

  • 15. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB.
    J Hypertens; 2008 Jun 12; 26(6):1244-9. PubMed ID: 18475164
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.